Technical Analysis for OXB - Oxford Biomedica Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Up 5 Days in a Row | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% |
| Alert | Time |
|---|---|
| Up 2% | about 13 hours ago |
| Possible Inside Day | about 14 hours ago |
| Fell Below Upper Bollinger Band | about 16 hours ago |
| Down 2% | about 16 hours ago |
| 1.5x Volume Pace | about 17 hours ago |
Free Daily (Stock) Chart Reading
Oxford Biomedica Plc Description
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D segment is engaged in the development of in-vivo and ex-vivo gene and cell therapy products, and the development of lentivirus-related platform technology. The Company provides a platform of technologies and capabilities with which it designs, develops and produces gene and cell-based medicines. The Company's product pipeline of OXB-102, OXB-201, OXB-202 and OXB-302 addresses neurodegenerative and ocular diseases, and a range of cancers. OXB-102 is indicated for Parkinson's disease. OXB-202 is indicated for Ocular (corneal graft rejection). OXB-302 is indicated for cancer disease. Its OXB-201 is indicated for wet age-related macular degeneration.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Disease Pipe Diseases Xf Therapy Cell Therapy Cancers Parkinson's Disease Platform Technology Gene Delivery Bioprocessing Cell Therapy Product Viral Vector Virotherapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 474.28 |
| 52 Week Low | 164.288 |
| Average Volume | 341,625 |
| 200-Day Moving Average | 240.68 |
| 50-Day Moving Average | 199.88 |
| 20-Day Moving Average | 216.93 |
| 10-Day Moving Average | 232.60 |
| Average True Range | 15.22 |
| RSI (14) | 85.38 |
| ADX | 37.96 |
| +DI | 40.10 |
| -DI | 5.17 |
| Chandelier Exit (Long, 3 ATRs) | 244.17 |
| Chandelier Exit (Short, 3 ATRs) | 233.49 |
| Upper Bollinger Bands | 268.91 |
| Lower Bollinger Band | 164.95 |
| Percent B (%b) | 1.17 |
| BandWidth | 47.93 |
| MACD Line | 17.75 |
| MACD Signal Line | 9.52 |
| MACD Histogram | 8.2228 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 317.75 | ||||
| Resistance 3 (R3) | 315.00 | 302.00 | 312.63 | ||
| Resistance 2 (R2) | 302.00 | 294.17 | 303.38 | 310.92 | |
| Resistance 1 (R1) | 294.50 | 289.33 | 298.25 | 297.25 | 309.21 |
| Pivot Point | 281.50 | 281.50 | 283.38 | 282.88 | 281.50 |
| Support 1 (S1) | 274.00 | 273.67 | 277.75 | 276.75 | 264.79 |
| Support 2 (S2) | 261.00 | 268.83 | 262.38 | 263.08 | |
| Support 3 (S3) | 253.50 | 261.00 | 261.38 | ||
| Support 4 (S4) | 256.25 |
